Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Ivermectin for Genital Warts
NCT07913321Not yet recruiting
- Sponsor
- University of Health Sciences Lahore
- Start
- Feb 2027
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Open-label, single-arm trial of CHILD-IVITAB in genital warts, sponsored by University of Health Sciences Lahore. Primary endpoint: Complete Wart Clearance at 8 weeks. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
CHILD-IVITAB
03
Conditions
genital warts
Beyond the preview
Go deeper on NCT07913321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07913321.